What started as an initiative to understand JAK-STAT pathway genes that are somatically altered in varying combinations and frequencies across diverse cancer types has now resulted in a framework that supports selective targeting of novel candidates in a broad spectrum of cancers. The gene discussed is SOAT1; the disease is cancer.